| Name | Title | Contact Details |
|---|
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
Personal Insurance Administrators is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adarza BioSystems, Inc. manufactures a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.